Abstract
The most popular current hypothesis is that Alzheimers disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ- secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective druglike molecule targeting novel mechanisms of BACE-1 regulation.
Keywords: BACE-1, Secretase, Memapsin, Alzheimer, Amyloid, Aspartyl protease
CNS & Neurological Disorders - Drug Targets
Title: Beta-Secretase: Structure, Function, and Evolution
Volume: 7 Issue: 3
Author(s): Chitra Venugopal, Christina M. Demos, K. S. Jagannatha Rao, Miguel A. Pappolla and Kumar Sambamurti
Affiliation:
Keywords: BACE-1, Secretase, Memapsin, Alzheimer, Amyloid, Aspartyl protease
Abstract: The most popular current hypothesis is that Alzheimers disease (AD) is caused by aggregates of the amyloid peptide (Aβ), which is generated by cleavage of the Aβ protein precursor (APP) by β-secretase (BACE-1) followed by γ- secretase. BACE-1 cleavage is limiting for the production of Aβ, making it a particularly good drug target for the generation of inhibitors that lower Aβ. A landmark discovery in AD was the identification of BACE-1 (a.k.a. Memapsin-2) as a novel class of type I transmembrane aspartic protease. Although BACE-2, a homologue of BACE-1, was quickly identified, follow up studies using knockout mice demonstrated that BACE-1 was necessary and sufficient for most neuronal Aβ generation. Despite the importance of BACE-1 as a drug target, development has been slow due to the incomplete understanding of its function and regulation and the difficulties in developing a brain penetrant drug that can specifically block its large catalytic pocket. This review summarizes the biological properties of BACE-1 and attempts to use phylogenetic perspectives to understand its function. The article also addresses the challenges in discovering a selective druglike molecule targeting novel mechanisms of BACE-1 regulation.
Export Options
About this article
Cite this article as:
Venugopal Chitra, Demos M. Christina, Jagannatha Rao S. K., Pappolla A. Miguel and Sambamurti Kumar, Beta-Secretase: Structure, Function, and Evolution, CNS & Neurological Disorders - Drug Targets 2008; 7 (3) . https://dx.doi.org/10.2174/187152708784936626
DOI https://dx.doi.org/10.2174/187152708784936626 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genotyping OLR1 Gene: A Genomic Biomarker for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry The Use of Antibody Engineering to Create Novel Drugs that Target N-methyl-D-Aspartate Receptors
Current Drug Targets Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry HumDLoc: Human Protein Subcellular Localization Prediction Using Deep Neural Network
Current Genomics The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Recent Advances of Dendrimers in Delivery of Genes and Drugs
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member:
Current Alzheimer Research L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Brain Structural Effects of Psychopharmacological Treatment in Bipolar Disorder
Current Neuropharmacology Acute and Chronic Stress-Induced Disturbances of Microglial Plasticity, Phenotype and Function
Current Drug Targets Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?
Current Alzheimer Research Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design The Phosphodiesterase III Inhibitor Cilostazol Ameliorates Ethanolinduced Endothelial Dysfunction
Current Neurovascular Research Alzheimers Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies
Current Drug Targets - CNS & Neurological Disorders Dietary Supplementation of Curcumin Alleviates NF-κB-dependent Skeletal Muscle Wasting in Rat
Endocrine, Metabolic & Immune Disorders - Drug Targets